CN102395361A - 非晶形α-(N-磺酰氨基)乙酰胺化合物的生物可利用胶囊组合物 - Google Patents

非晶形α-(N-磺酰氨基)乙酰胺化合物的生物可利用胶囊组合物 Download PDF

Info

Publication number
CN102395361A
CN102395361A CN2010800164919A CN201080016491A CN102395361A CN 102395361 A CN102395361 A CN 102395361A CN 2010800164919 A CN2010800164919 A CN 2010800164919A CN 201080016491 A CN201080016491 A CN 201080016491A CN 102395361 A CN102395361 A CN 102395361A
Authority
CN
China
Prior art keywords
capsule
peg
pharmaceutical composition
crystallization inhibitor
sulfonyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2010800164919A
Other languages
English (en)
Chinese (zh)
Inventor
S.钱德兰
R.B.甘地
J.K.莱丰斯
R.K.佩罗内
C.P.普赖斯
K.S.拉哈文
I.乌拉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of CN102395361A publication Critical patent/CN102395361A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN2010800164919A 2009-04-14 2010-04-13 非晶形α-(N-磺酰氨基)乙酰胺化合物的生物可利用胶囊组合物 Pending CN102395361A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16906109P 2009-04-14 2009-04-14
US61/169061 2009-04-14
PCT/US2010/030862 WO2010120755A1 (en) 2009-04-14 2010-04-13 Bioavailable capsule compositions of amorphous alpha-(n-sulfonamido)acetamide compound

Publications (1)

Publication Number Publication Date
CN102395361A true CN102395361A (zh) 2012-03-28

Family

ID=42235859

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2010800164919A Pending CN102395361A (zh) 2009-04-14 2010-04-13 非晶形α-(N-磺酰氨基)乙酰胺化合物的生物可利用胶囊组合物

Country Status (14)

Country Link
US (1) US8252821B2 (enExample)
EP (1) EP2419090B1 (enExample)
JP (1) JP2012524092A (enExample)
KR (1) KR20120022766A (enExample)
CN (1) CN102395361A (enExample)
AR (1) AR076305A1 (enExample)
AU (1) AU2010236602A1 (enExample)
BR (1) BRPI1015483A2 (enExample)
CA (1) CA2758847A1 (enExample)
EA (1) EA201101286A1 (enExample)
MX (1) MX2011010514A (enExample)
NZ (1) NZ595335A (enExample)
TW (1) TW201041609A (enExample)
WO (1) WO2010120755A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113473971A (zh) * 2019-02-22 2021-10-01 詹森药业有限公司 药物配制品

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ533603A (en) 2001-12-20 2007-02-23 Bristol Myers Squibb Co Alpha-(N-sulphonamido)acetamide derivatives as beta-amyloid inhibitors used for treating Alzheimer's Disease and Down's syndrome
US8044077B2 (en) 2009-03-19 2011-10-25 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compounds incorporating deuterium as inhibitors of beta amyloid peptide production
US7977362B2 (en) 2009-03-20 2011-07-12 Bristol-Myers Squibb Company Alpha-(N-benzenesulfonamido)cycloalkyl derivatives
EP2485416A4 (en) 2009-10-02 2017-04-05 LG Electronics Inc. Transmission method and device for a downlink reference signal
NZ613167A (en) * 2010-12-16 2015-09-25 Univ Texas Azole pharmaceutical formulations for parenteral administration and methods for preparing and using the same as treatment of diseases sensitive to azole compounds
US9364433B2 (en) 2011-04-28 2016-06-14 Borje S. Andersson Parenteral formulations of lipophilic pharmaceutical agents and methods for preparing and using the same
US20130302414A1 (en) * 2012-05-07 2013-11-14 Bristol-Myers Squibb Company Solubilized capsule formulation of 1,1-dimethylethyl [(1s)-1-carbamoyl)pyrrolidin-1-yl]carbonyl}-2,2-dimethylpropyl]carbamate
TWI795381B (zh) 2016-12-21 2023-03-11 比利時商健生藥品公司 作為ｍａｌｔ１抑制劑之吡唑衍生物
BR112021019799A2 (pt) 2019-04-11 2021-12-07 Janssen Pharmaceutica Nv Derivados contendo anéis de piridina como inibidores de malt1
JP2023538099A (ja) * 2020-08-21 2023-09-06 ヤンセン ファーマシューティカ エヌ．ベー． Ｍａｌｔ１阻害剤と、ポリエチレングリコールの脂肪酸との混合物と、を含む、医薬製剤

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003053912A1 (en) * 2001-12-20 2003-07-03 Bristol-Myers Squibb Company α-(N-SULPHONAMIDO)ACETAMIDE DERIVATIVES AS β-AMYLOID INHIBITORS
CN101098683A (zh) * 2004-12-14 2008-01-02 惠氏公司 5-ht6激动剂用于治疗和预防神经退化性疾病的用途
CN101400349A (zh) * 2006-03-01 2009-04-01 罗斯坎普研究有限责任公司 抑制β-淀粉样蛋白产生的化合物

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5274094A (en) 1990-08-15 1993-12-28 British Bio-Technology Limited Production of heterobicyclic containing benzene sulfonamides
GB9202791D0 (en) 1992-02-11 1992-03-25 British Bio Technology Compounds
NZ321293A (en) 1995-11-17 2001-04-27 Warner Lambert Co Sulfonamide inhibitors of matrix metalloproteinases
CZ16899A3 (cs) 1996-07-22 1999-08-11 Monsanto Company Thiolsulfonamidové inhibitory metaloproteázy
CA2264718C (en) * 1996-09-01 2006-05-30 Pharmos Corporation Solid coprecipitates for enhanced bioavailability of lipophilic substances
JPH11343279A (ja) 1998-03-16 1999-12-14 Shionogi & Co Ltd スルホンアミド誘導体およびそれらを含有するＴＮＦ―α産生抑制剤
US6313123B1 (en) 1999-01-27 2001-11-06 American Cyanamid Company Acetylenic sulfonamide thiol tace inhibitors
JP2002535386A (ja) 1999-01-27 2002-10-22 アメリカン・サイアナミド・カンパニー アセチレンスルホンアミドチオールｔａｃｅインヒビター
NZ514453A (en) 1999-02-26 2003-04-29 Merck & Co Inc Novel sulfonamide compounds and uses thereof
DE60233150D1 (de) * 2001-10-19 2009-09-10 Isotechnika Inc Neue cyclosporin-analoge mikroemulsionsvorkonzentrate
RU2342374C2 (ru) 2003-03-31 2008-12-27 Уайт Фтор- и трифторалкилсодержащие гетероциклические сульфонамидные ингибиторы образования бета-амилоида и их производные
RU2364587C2 (ru) 2003-10-29 2009-08-20 Элан Фармасьютикалз, Инк. N-замещенные бензолсульфонамиды
US7163942B2 (en) 2004-04-01 2007-01-16 Pfizer Inc. Sulfonamide compounds for the treatment of neurodegenerative disorders
EP1744731A1 (en) * 2004-04-28 2007-01-24 Procarrier, Inc. Oral formulation for delivery of poorly absorbed drugs
JP4845883B2 (ja) 2004-07-13 2011-12-28 エフ．ホフマン−ラ ロシュ アーゲー スルホンアミド誘導体
US7144894B2 (en) 2004-09-23 2006-12-05 Bristol-Myers Squibb Company Sulfonamide bicyclic compounds
TW200732295A (en) 2006-02-17 2007-09-01 Wyeth Corp Selective N-sulfonylation of 2-amino trifluoroalkyl substituted alcohols
PE20080169A1 (es) 2006-02-17 2008-04-11 Wyeth Corp Metodo para preparar alcoholes sustituidos con sulfonamidas y sus compuestos intermedios
US8633179B2 (en) 2007-03-13 2014-01-21 The Trustees Of Columbia University In The City Of New York Synergistic interaction of NOTCH-1 inhibitors with glucocorticoids
WO2009005688A2 (en) 2007-06-29 2009-01-08 Trustees Of Columbia University In The City Of New York Activating mutations in notch-1
US8084477B2 (en) 2007-10-31 2011-12-27 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production
WO2009137657A1 (en) 2008-05-08 2009-11-12 Bristol-Myers Squibb Company 2-aryl glycinamide derivatives
KR20110133046A (ko) 2009-03-19 2011-12-09 브리스톨-마이어스 스큅 컴퍼니 베타 아밀로이드 펩티드 생성의 억제제로서의 신규 알파-(ｎ-술폰아미도)아세트아미드 화합물
US8044077B2 (en) 2009-03-19 2011-10-25 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compounds incorporating deuterium as inhibitors of beta amyloid peptide production
US7977362B2 (en) 2009-03-20 2011-07-12 Bristol-Myers Squibb Company Alpha-(N-benzenesulfonamido)cycloalkyl derivatives
US20110071199A1 (en) 2009-03-20 2011-03-24 Bristol-Myers Squibb Company Thiophenyl Sulfonamides for the Treatment of Alzheimer's Disease
TW201043269A (en) 2009-04-14 2010-12-16 Bristol Myers Squibb Co Bioavailable compositions of amorphous alpha-(N-sulfonamido)acetamide compound

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003053912A1 (en) * 2001-12-20 2003-07-03 Bristol-Myers Squibb Company α-(N-SULPHONAMIDO)ACETAMIDE DERIVATIVES AS β-AMYLOID INHIBITORS
CN101098683A (zh) * 2004-12-14 2008-01-02 惠氏公司 5-ht6激动剂用于治疗和预防神经退化性疾病的用途
CN101400349A (zh) * 2006-03-01 2009-04-01 罗斯坎普研究有限责任公司 抑制β-淀粉样蛋白产生的化合物

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113473971A (zh) * 2019-02-22 2021-10-01 詹森药业有限公司 药物配制品
CN113473971B (zh) * 2019-02-22 2024-07-02 詹森药业有限公司 药物配制品

Also Published As

Publication number Publication date
US20100260837A1 (en) 2010-10-14
TW201041609A (en) 2010-12-01
BRPI1015483A2 (pt) 2016-04-26
JP2012524092A (ja) 2012-10-11
AR076305A1 (es) 2011-06-01
WO2010120755A1 (en) 2010-10-21
NZ595335A (en) 2013-03-28
CA2758847A1 (en) 2010-10-21
AU2010236602A1 (en) 2011-10-13
EP2419090A1 (en) 2012-02-22
EA201101286A1 (ru) 2012-04-30
US8252821B2 (en) 2012-08-28
MX2011010514A (es) 2011-11-29
EP2419090B1 (en) 2013-02-13
KR20120022766A (ko) 2012-03-12

Similar Documents

Publication Publication Date Title
CN102395361A (zh) 非晶形α-(N-磺酰氨基)乙酰胺化合物的生物可利用胶囊组合物
ES2287333T3 (es) Comprimidos de tamsulosina de liberacion modificada.
ES2340997T3 (es) Composiciones orales para el tratamiento de diabetes.
ES2380747T3 (es) Métodos y medicamentos para administración de ibuprofeno
PT1432408E (pt) Composições farmacêuticas que compreendem dióxido de silício coloidal
PT2066325E (pt) Composições farmacêuticas de aripiprazol
MXPA06000529A (es) Formulaciones farmaceuticas utiles para inhibir la secrecion de acido y metodos para elaborarlas y utilizarlas.
NZ768958A (en) Methods for treating subjects with prader-willi syndrome or smith-magenis syndrome
BR112012023654B1 (pt) Método para produzir grânulos contendo agente anticoagulante e método para produzir uma composição farmacêutica contendo o dito agente
CN102387788B (zh) 非晶型α-(N-磺酰氨基)乙酰胺化合物的生物可利用组合物
CN103889455A (zh) 稳定化乙哌立松医药组成物及含有上述组成物的缓释制剂
WO2017160345A1 (en) Palatable compositions including sodium phenylbutyrate and uses thereof
CN100388918C (zh) 含有氮杂环丁烷衍生物的药物组合物
RU2690685C2 (ru) Фармацевтические композиции, содержащие алпелисиб
CZ20021315A3 (cs) Jednotka dávkování
JP2011517678A (ja) 過活動膀胱の治療のためのウデナフィル、およびアルフゾシンまたはオキシブチニンの組み合わせの使用
TWI859242B (zh) 嘧啶基胺基-吡唑化合物之修飾釋放調配物及治療方法
CN1717252B (zh) 含有碱性药物的制剂
JPWO2003075919A1 (ja) 塩酸ピルジカイニド含有錠剤（乾式）
ES2785398T3 (es) Composición farmacéutica que comprende Aripiprazol o sal del mismo
WO2016054240A1 (en) Fixed dose combinations for the treatment of viral diseases
JPWO2003075918A1 (ja) 塩酸ピルジカイニド含有錠剤（湿式）
JP2021172612A (ja) オキシトシンおよびプロトンポンプ阻害剤の組み合わせを含む薬剤
CA3217167A1 (en) Alpelisib formulation
BR112019004479B1 (pt) Comprimido prensado de liberação imediata para suprimento oral de carbamato de (r)-2-amino-3- fenilpropila, e seu uso

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20120328